{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:06:13Z","timestamp":1790723173233,"version":"4.1.0"},"reference-count":44,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FEDER\u2014Fundo Europeu de Desenvolimento Regional","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"FEDER\u2014Fundo Europeu de Desenvolimento Regional","award":["PRR-09\/C06-834I07\/2024.P11721"],"award-info":[{"award-number":["PRR-09\/C06-834I07\/2024.P11721"]}]},{"name":"FEDER\u2014Fundo Europeu de Desenvolimento Regional","award":["2024.18026.PEX"],"award-info":[{"award-number":["2024.18026.PEX"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background: HER2-low breast cancer is a biologically heterogeneous subgroup in which hormone receptor (HR) expression critically shapes prognosis and treatment, but the underlying regulatory mechanisms remain unclear. MicroRNAs (miRNAs) are key post-transcriptional regulators of gene expression and may contribute to HR heterogeneity. This study aimed to identify deregulated miRNAs and associated gene networks distinguishing HER2-low\/HR-positive from HER2-low\/HR-negative tumors, elucidating the molecular mechanisms underlying this divergence. Methods: Differential expression analyses of miRNAs and genes were performed using Wilcoxon tests and DESeq2 (|log2FC| &gt; 1; FDR-adjusted p-value &lt; 0.05). Survival analyses were conducted using Cox proportional hazards models to evaluate the individual miRNAs and miRNA signature. Functional enrichment analyses, including GO, KEGG and Reactome pathways, were performed. Correlation analysis and the miRNA target prediction were integrated to identify regulatory interactions. Results: Comparisons between HER2-low\/HR-positive and HER2-low\/HR-negative tumors identified 165 significantly deregulated miRNAs and 170 strongly deregulated genes. Intersection analysis highlighted miR-9-5p, miR-532-5p and miR-576-5p as specifically associated with HR-negative status. Survival analyses showed non-significant trends for the overall survival and progression-free interval. Functional enrichment analysis revealed hormone-related pathways in HR-positive tumors and immune, inflammatory and proliferative pathways in HR-negative tumors. Integrative correlation and target prediction analyses identified two miRNA\u2013mRNA regulatory axes, miR-576-5p\/TGFBI and miR-9-5p\/POU2F2. Conclusions: Our study demonstrated that HER2-low breast cancer exhibits distinct miRNA and gene expression profiles, which highlight different transcriptomic profiles according to HR status for the first time. Specific miRNA\u2013gene networks may drive transcriptional heterogeneity, serving as potential biomarkers for stratification and as therapeutic targets. These findings provide insight into the molecular basis of HER2-low tumor diversity and support future development of HR-directed therapeutic strategies.<\/jats:p>","DOI":"10.3390\/genes17030305","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:48:56Z","timestamp":1772542136000},"page":"305","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MicroRNA\u2013Gene Networks Distinguish Hormone Receptor Status in HER2-Low Breast Cancer: An Integrative Transcriptomic Analysis"],"prefix":"10.3390","volume":"17","author":[{"given":"Eduarda","family":"Carvalho","sequence":"first","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Pathology, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0938-1543","authenticated-orcid":false,"given":"Andreia","family":"Brand\u00e3o","sequence":"additional","affiliation":[{"name":"Cancer Genetics Group, IPO Porto Research Center (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-6946","authenticated-orcid":false,"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Pathology, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast Cancer: Pathogenesis and Treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pathol.2016.10.012","article-title":"Molecular Classification of Breast Cancer: What the Pathologist Needs to Know","volume":"49","author":"Rakha","year":"2017","journal-title":"Pathology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5858\/arpa.2022-0070-RA","article-title":"Molecular Classification of Breast Cancer: Relevance and Challenges","volume":"147","author":"Zhang","year":"2023","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO Expert Consensus Statements (ECS) on the Definition, Diagnosis, and Management of HER2-Low Breast Cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Andr\u00e9, C., Bertaut, A., Ladoire, S., Desmoulins, I., Jankowski, C., Beltjens, F., Charon-Barra, C., Bergeron, A., Richard, C., and Boidot, R. (2024). HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity. Cancers, 16.","DOI":"10.3390\/cancers16112009"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s12094-025-04053-2","article-title":"Comparison of Clinical Characteristics and Survival between HER2-Zero and HER2-Low in Early Breast Cancer: A Retrospective Observational Study","volume":"28","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4143\/crt.2023.1138","article-title":"HER2-Low Breast Cancer: Now and in the Future","volume":"56","author":"Kang","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2853007","DOI":"10.1155\/2024\/2853007","article-title":"Insights into the Emerging Entity of HER2-Low Breast Cancer","volume":"2024","author":"Diab","year":"2024","journal-title":"Int. J. Breast Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12282-021-01303-3","article-title":"The Frequency of Low HER2 Expression in Breast Cancer and a Comparison of Prognosis between Patients with HER2-Low and HER2-Negative Breast Cancer by HR Status","volume":"29","author":"Horisawa","year":"2022","journal-title":"Breast Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1002\/jcp.27486","article-title":"An Overview of MicroRNAs: Biology, Functions, Therapeutics, and Analysis Methods","volume":"234","author":"Saliminejad","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sadakierska-Chudy, A. (2020). MicroRNAs: Diverse Mechanisms of Action and Their Potential Applications as Cancer Epi-Therapeutics. Biomolecules, 10.","DOI":"10.3390\/biom10091285"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wong, J.S., and Cheah, Y.K. (2020). Potential MiRNAs for MiRNA-Based Therapeutics in Breast Cancer. Noncoding RNA, 6.","DOI":"10.3390\/ncrna6030029"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s11010-021-04065-w","article-title":"Twist Activates MiR-22 to Suppress Estrogen Receptor Alpha in Breast Cancer","volume":"476","author":"Vesuna","year":"2021","journal-title":"Mol. Cell Biochem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/j.1742-4658.2010.07594.x","article-title":"An Estrogen Receptor \u03b1 Suppressor, MicroRNA-22, Is Downregulated in Estrogen Receptor \u03b1-Positive Human Breast Cancer Cell Lines and Clinical Samples","volume":"277","author":"Xiong","year":"2010","journal-title":"FEBS J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13058-022-01597-x","article-title":"Progesterone Modulates the DSCAM-AS1\/MiR-130a\/ESR1 Axis to Suppress Cell Invasion and Migration in Breast Cancer","volume":"24","author":"Yadav","year":"2022","journal-title":"Breast Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8332","DOI":"10.1158\/0008-5472.CAN-09-2206","article-title":"Widespread Estrogen-Dependent Repression of MicroRNAs Involved in Breast Tumor Cell Growth","volume":"69","author":"Maillot","year":"2009","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ninio-Many, L., Hikri, E., Burg-Golani, T., Stemmer, S.M., Shalgi, R., and Ben-Aharon, I. (2020). MiR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00191"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18295","DOI":"10.18632\/oncotarget.7577","article-title":"A Novel Double-Negative Feedback Loop between MiR-489 and the HER2-SHP2-MAPK Signaling Axis Regulates Breast Cancer Cell Proliferation and Tumor Growth","volume":"7","author":"Patel","year":"2016","journal-title":"Oncotarget"},{"key":"ref_22","first-page":"167783","article-title":"Micro-RNAs Targeting the Estrogen Receptor Alpha Involved in Endocrine Therapy Resistance in Breast Cancer","volume":"1871","author":"Lizano","year":"2025","journal-title":"BBA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s10020-025-01163-z","article-title":"Involvement of MicroRNAs-449\/FASN Axis in Response to Trastuzumab Therapy in HER2-Positive Breast Cancer","volume":"31","author":"Lameirinhas","year":"2025","journal-title":"Mol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"110636","DOI":"10.1016\/j.cellsig.2023.110636","article-title":"MiR-199a-3p Promotes Gastric Cancer Progression by Promoting Its Stemness Potential via DDR2 Mediation","volume":"106","author":"Ren","year":"2023","journal-title":"Cell Signal"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/EDBK_201313","article-title":"New and Important Changes in the TNM Staging System for Breast Cancer","volume":"38","author":"Hortobagyi","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00428-018-2301-9","article-title":"The New TNM-Based Staging of Breast Cancer","volume":"472","author":"Cserni","year":"2018","journal-title":"Virchows Arch."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Xia, L.Y., Cao, X.C., Hu, Q.L., and Xu, W.Y. (2024). Prognosis in HR-Positive Metastatic Breast Cancer with HER2-Low versus HER2-Zero Treated with CDK4\/6 Inhibitor and Endocrine Therapy: A Meta-Analysis. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1413674"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"You, S., Gong, C., Li, Y., Xie, Y., Li, Y., Zhao, Y., and Wang, B. (2023). Clinicopathological Characteristics, Evolution, Treatment Pattern and Outcomes of Hormone-Receptor-Positive\/HER2-Low Metastatic Breast Cancer. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1270453"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"45283","DOI":"10.1038\/srep45283","article-title":"Stepwise Analysis of MIR9 Loci Identifies MiR-9-5p to Be Involved in Oestrogen Regulated Pathways in Breast Cancer Patients","volume":"7","author":"Barbano","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Bandini, E., Fanini, F., Vannini, I., Rossi, T., Plousiou, M., Tumedei, M.M., Limarzi, F., Maltoni, R., Fabbri, F., and Hrelia, S. (2020). MiR-9-5p as a Regulator of the Androgen Receptor Pathway in Breast Cancer Cell Lines. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.579160"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12935-021-01944-6","article-title":"Correction to: Exosomes from Tamoxifen-Resistant Breast Cancer Cells Transmit Drug Resistance Partly by Delivering MiR-9-5p","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_32","first-page":"400","article-title":"MiR-532-5p Promotes Breast Cancer Proliferation and Migration by Targeting RERG","volume":"19","author":"Huang","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"42259","DOI":"10.1074\/jbc.M105888200","article-title":"RERG Is a Novel Ras-Related, Estrogen-Regulated and Growth-Inhibitory Gene in Breast Cancer","volume":"276","author":"Finlin","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.31661\/gmj.v8i0.1646","article-title":"Expression of Bioinformatically Candidate MiRNAs Including, MiR-576-5p, MiR-501-3p and MiR-3143, Targeting PI3K Pathway in Triple-Negative Breast Cancer","volume":"8","author":"Hadavi","year":"2019","journal-title":"Galen. Med. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, Pathological, and PAM50 Gene Expression Features of HER2-Low Breast Cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Agostinetto, E., Rediti, M., Fimereli, D., Debien, V., Piccart, M., Aftimos, P., Sotiriou, C., and de Azambuja, E. (2021). Her2-Low Breast Cancer: Molecular Characteristics and Prognosis. Cancers, 13.","DOI":"10.3390\/cancers13112824"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"oyaf081","DOI":"10.1093\/oncolo\/oyaf081","article-title":"Exploring Immune Activation Patterns in HER2-Low and HER2-Ultralow Breast Cancer Subtypes","volume":"30","author":"Santarpia","year":"2025","journal-title":"Oncologist"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"217865","DOI":"10.1016\/j.canlet.2025.217865","article-title":"The Role of Tumor Microenvironment and Immune Cell Crosstalk in Triple-Negative Breast Cancer (TNBC): Emerging Therapeutic Opportunities","volume":"628","author":"Sabit","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s40364-025-00850-7","article-title":"THSD4 Is a Novel Mediator of T Cell Exclusion and Anti-PD-1 Resistance in Hormone Receptor-Positive Breast Cancer","volume":"13","author":"Walker","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/s13058-014-0464-0","article-title":"Shift in GATA3 Functions, and GATA3 Mutations, Control Progression and Clinical Presentation in Breast Cancer","volume":"16","author":"Cohen","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_41","unstructured":"(2026, January 09). miRDB. Available online: https:\/\/mirdb.org\/faq.html."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1002\/1878-0261.12828","article-title":"TGFBI Modulates Tumour Hypoxia and Promotes Breast Cancer Metastasis","volume":"14","author":"Fico","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.ajpath.2011.12.035","article-title":"Transforming Growth Factor Beta-Induced (TGFBI) Is an Anti-Adhesive Protein Regulating the Invasive Growth of Melanoma Cells","volume":"180","author":"Nummela","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1111\/cas.70093","article-title":"OCT-2 Is Associated with Pro-Metastatic Epigenomic Properties of Triple-Negative Breast Cancer Cells","volume":"116","author":"Ogikubo","year":"2025","journal-title":"Cancer Sci."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/3\/305\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:02:28Z","timestamp":1772712148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/3\/305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["genes17030305"],"URL":"https:\/\/doi.org\/10.3390\/genes17030305","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}